FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2065293722> ?p ?o ?g. }

• W2065293722 endingPage "97" @default.
• W2065293722 startingPage "91" @default.
• W2065293722 abstract "La hemorragia posparto supone la pérdida de más de 500 ml de sangre tras un parto vaginal o de más de 1.000 ml tras una cesárea en las primeras 24 h posparto. Aunque la incidencia de muerte materna por hemorragia posparto ha disminuido, esta continúa siendo la causa más frecuente de muerte materna por hemorragia obstétrica. La incidencia de atonía uterina, primera causa de hemorragia posparto, va en aumento tanto en el parto vaginal como en la cesárea. Aunque en más de dos terceras partes las hemorragias posparto tienen lugar en pacientes sin factores de riesgo identificables, el tercer estadio del parto prolongado es el principal factor de riesgo. El manejo activo de este periodo incluye la administración de uterotónicos, fármacos que producen una contracción uterina adecuada, tras el nacimiento del neonato. Se puede administrarlos de forma profiláctica o terapéutica. Se ha comprobado que la administración profiláctica se relaciona con un tercer estadio más corto, menor riesgo de hemorragia y menor necesidad de uterotónicos adicionales. Actualmente existen cuatro fármacos o grupos de fármacos con actividad uterotónica: oxitocina, carbetocina, alcaloides del cornezuelo del centeno y prostaglandinas. Aunque la literatura es heterogénea, la oxitocina es el uterotónico de elección en la profilaxis y el tratamiento de la hemorragia posparto, pero se debe disminuir la dosis; la metilergometrina es uterotónico de segunda línea en la profilaxis y el tratamiento; a pesar de los efectos secundarios, el carboprost (prostaglandina F2α) es la prostaglandina de elección en el tratamiento de la hemorragia; el misoprostol puede ser una alternativa a la oxitocina, y el uso profiláctico de carbetocina debe individualizarse. Postpartum haemorrhage (PPH) is defined by the WHO as a blood loss >500 mL after vaginal delivery or >1000 mL after caesarean section during the first 24 hours post-delivery. Although the incidence of maternal mortality caused by PPH has decreased, it continues to be the major cause of maternal mortality due to obstetric haemorrhage. Furthermore, the incidence of uterine atony, which is the most prevalent cause of PPH, is still increasing in both vaginal delivery and caesarean section. Although PPH occurs in more than two thirds of patients without any identifiable risk factor, a prolonged third stage of labour is the main risk factor. Active management of the third stage of labour has been postulated to reduce the risk of bleeding in this period. It includes the administration of uterotonic agents after the birth of the baby. Uterotonic agents are defined as drugs that produce adequate uterine contraction. These drugs can be used as prophylactic therapy or treatment. The prophylactic use of uterotonic agents has been reported to be associated with a shorter third stage of labour, less risk of PPH and less need of additional uterotonic agents. There are currently four drugs or groups of drugs with uterotonic action: oxytocin, carbetocin, ergot derivatives and prostaglandins. The literature on this subject is extensive, heterogeneous and sometimes discordant. Oxytocin is still the first-line uterotonic drug for prophylaxis and treatment of uterine atony. There is a common trend to use high doses of uterotonics for fear of inadequate uterine contraction, but the current literature recommends its reduction. Methylergonovine continues being the second-line uterotonic agent in the prophylaxis and treatment of PPH, because of its side effects. Despite carboprost (PGF2α) side effects, it is still the first-line prostaglandin for PPH treatment. Misoprostol may be an alternative to oxytocin when it is not available, although it needs further studies to support this. Finally, the prophylactic use of carbetocin should be individualised." @default.
• W2065293722 created "2016-06-24" @default.
• W2065293722 creator A5010782918 @default.
• W2065293722 creator A5014232541 @default.
• W2065293722 creator A5043966245 @default.
• W2065293722 creator A5048433520 @default.
• W2065293722 creator A5056832790 @default.
• W2065293722 creator A5074424044 @default.
• W2065293722 date "2012-02-01" @default.
• W2065293722 modified "2023-10-16" @default.
• W2065293722 title "Actualización en el uso de uterotónicos" @default.
• W2065293722 cites W1918400116 @default.
• W2065293722 cites W1967838077 @default.
• W2065293722 cites W2023063533 @default.
• W2065293722 cites W2033605703 @default.
• W2065293722 cites W2036492466 @default.
• W2065293722 cites W2037158282 @default.
• W2065293722 cites W2051015344 @default.
• W2065293722 cites W2053021710 @default.
• W2065293722 cites W2057572970 @default.
• W2065293722 cites W2063397475 @default.
• W2065293722 cites W2065676624 @default.
• W2065293722 cites W2070009653 @default.
• W2065293722 cites W2071131834 @default.
• W2065293722 cites W2074131571 @default.
• W2065293722 cites W2089277892 @default.
• W2065293722 cites W2098683876 @default.
• W2065293722 cites W2102488634 @default.
• W2065293722 cites W2102698323 @default.
• W2065293722 cites W2119602371 @default.
• W2065293722 cites W2120511870 @default.
• W2065293722 cites W2126296928 @default.
• W2065293722 cites W2129751766 @default.
• W2065293722 cites W2130695750 @default.
• W2065293722 cites W2133223545 @default.
• W2065293722 cites W2150655622 @default.
• W2065293722 cites W2165181648 @default.
• W2065293722 cites W2319583780 @default.
• W2065293722 cites W35506279 @default.
• W2065293722 doi "https://doi.org/10.1016/j.redar.2012.02.019" @default.
• W2065293722 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22480555" @default.
• W2065293722 hasPublicationYear "2012" @default.
• W2065293722 type Work @default.
• W2065293722 sameAs 2065293722 @default.
• W2065293722 citedByCount "6" @default.
• W2065293722 countsByYear W20652937222012 @default.
• W2065293722 countsByYear W20652937222016 @default.
• W2065293722 countsByYear W20652937222017 @default.
• W2065293722 countsByYear W20652937222021 @default.
• W2065293722 countsByYear W20652937222022 @default.
• W2065293722 crossrefType "journal-article" @default.
• W2065293722 hasAuthorship W2065293722A5010782918 @default.
• W2065293722 hasAuthorship W2065293722A5014232541 @default.
• W2065293722 hasAuthorship W2065293722A5043966245 @default.
• W2065293722 hasAuthorship W2065293722A5048433520 @default.
• W2065293722 hasAuthorship W2065293722A5056832790 @default.
• W2065293722 hasAuthorship W2065293722A5074424044 @default.
• W2065293722 hasConcept C138885662 @default.
• W2065293722 hasConcept C15708023 @default.
• W2065293722 hasConcept C29456083 @default.
• W2065293722 hasConcept C71924100 @default.
• W2065293722 hasConceptScore W2065293722C138885662 @default.
• W2065293722 hasConceptScore W2065293722C15708023 @default.
• W2065293722 hasConceptScore W2065293722C29456083 @default.
• W2065293722 hasConceptScore W2065293722C71924100 @default.
• W2065293722 hasIssue "2" @default.
• W2065293722 hasLocation W20652937221 @default.
• W2065293722 hasLocation W20652937222 @default.
• W2065293722 hasOpenAccess W2065293722 @default.
• W2065293722 hasPrimaryLocation W20652937221 @default.
• W2065293722 hasRelatedWork W1506200166 @default.
• W2065293722 hasRelatedWork W1995515455 @default.
• W2065293722 hasRelatedWork W1999344589 @default.
• W2065293722 hasRelatedWork W2039318446 @default.
• W2065293722 hasRelatedWork W2080531066 @default.
• W2065293722 hasRelatedWork W2748952813 @default.
• W2065293722 hasRelatedWork W2789448498 @default.
• W2065293722 hasRelatedWork W2899084033 @default.
• W2065293722 hasRelatedWork W3032375762 @default.
• W2065293722 hasRelatedWork W3108674512 @default.
• W2065293722 hasVolume "59" @default.
• W2065293722 isParatext "false" @default.
• W2065293722 isRetracted "false" @default.
• W2065293722 magId "2065293722" @default.
• W2065293722 workType "article" @default.